Objective-ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type I repeats-13) prevents microvascular thrombosis by cleaving prothrombogenic ultralarge von Willebrand factor (VWF) multimers. Clinical studies have found association between reduced ADAMTS13-specific activity, ultralarge VWF multimers, and thrombotic angiopathy in patients with diabetic nephropathy. It remains unknown, however, whether ADAMTS13 deficiency or ultralarge VWF multimers have a causative effect in diabetic nephropathy. Approach and Results-The extent of renal injury was evaluated in wild-type (WT), Adamts13 −/− and Adamts13
D
iabetic nephropathy is the major cause of end-stage renal disease, contributing to ≈40% of new cases, and it is an independent risk factor for cardiovascular diseases.
1 Current strategies to treat diabetic nephropathy include glycemic control with antidiabetic drugs and antihypertensive medications, such as angiotensin-converting enzyme inhibitors. Despite therapy, several patients remain at high risk because of adverse events.
Chronic hyperglycemia and oxidative stress-induced endothelial dysfunction and platelet activation are key features of progressive diabetic nephropathy. 2 Oxidative stress was shown to be associated with accumulation of ultralarge von Willebrand factor (ULVWF) multimers and thrombotic angiopathy in patients with diabetic nephropathy. 3 Notably, ULVWF multimers, which are stored in platelet α-granules and endothelial Weibel-Palade bodies, are extremely large (up to 20 000 kDa) and are considered to be prothrombogenic.
ULVWF multimers are not present in the plasma of healthy individuals because, upon release from platelets or endothelial cells, they are rapidly cleaved by the plasma protease ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type I repeats-13) into less active, smaller VWF multimers. ADAMTS13 is synthesized primarily by hepatic stellate cells 4, 5 and to a lesser extent by endothelial cells, 6, 7 megakaryocytes, 8 and podocytes. 9 Deficiency of ADAMTS13 or low levels of ADAMTS13 (<10%) increases plasma levels of ULVWF and causes thrombotic thrombocytopenic purpura, a disorder of thrombotic microangiopathy. Recent clinical studies suggest that chronic hyperglycemia can imbalance ADAMTS13-VWF axis, and, thereby may potentially contribute to thrombotic angiopathy in the setting of diabetes mellitus. 10, 11 Despite these epidemiological findings, which predict that ADAMTS13-VWF axis imbalance may be causally linked to adverse renal and cardiovascular events in patients with diabetes mellitus, experimental evidence for causality is lacking.
Herein, we determined the role of the ADAMTS13-VWF axis in the progression of diabetic nephropathy by testing the hypothesis that ADAMTS13 deficiency exacerbates diabetic nephropathy by aggravating intrarenal thrombosis mediated by ULVWF. We used Adamts13
−/− (model of ULVWF multimers) 12 and Adamts13 −/− Vwf −/− mice 13 in an experimental model of streptozotocin-induced diabetic nephropathy. We found that ADAMTS13 deficiency exacerbated diabetic nephropathy, whereas deletion of VWF alleviated the aggravated diabetic nephropathy in Adamts13 −/− mice.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Wild-Type Diabetic Mice Exhibit Reduced Plasma ADAMTS13-Specific Activity and Increased VWF Levels
Reduced ADAMTS13-specific activity and elevated VWF levels have been reported in the plasma of patients with diabetic nephropathy. 10, 11, 14 We determined whether the progression of diabetic nephropathy in streptozotocininduced diabetes mellitus model would cause an increase in VWF levels associated with decreased ADAMTS13-specific activity. In wild-type (WT) diabetic mice, we found that plasma ADAMTS13-specific activity was markedly reduced by ≈46%, whereas plasma VWF levels were increased by 3.8-fold (P<0.05 versus WT nondiabetic mice, Figure 1A and 1B).
ADAMTS13 Deficiency Worsens Kidney Function During Progression of Diabetic Nephropathy
Next, we determined whether ADAMTS13 deficiency exacerbates diabetic nephropathy. As expected, induction of diabetes mellitus in WT mice significantly deteriorated kidney function as assessed by increased urinary albumin secretion, plasma creatinine, and urea levels concomitant with an increase in kidney weight (P<0.05 versus WT nondiabetic mice, Figure 2 ).
Adamts13
−/− diabetic mice exhibited further deterioration in kidney function compared with WT diabetic mice (P<0.05, Figure 2 ), which was independent of hyperglycemia and hypertension ( Figure SI through SIII in the online-only Data Supplement).
ADAMTS13 Deficiency Aggravates Intrarenal Thrombosis and Worsens Key Histological Features of Diabetic Nephropathy
ADAMTS13 is known to prevent thrombus formation in the microvasculature by cleaving prothrombotic ULVWF multmers. 12, 15 We hypothesized that ADAMTS13 deficiency aggravates intrarenal thrombosis, and thereby exacerbates diabetic nephropathy. To evaluate intrarenal thrombosis, we quantified intrarenal fibrin(ogen) deposition, VWF, plasminogen activator inhibitor (PAI-1), and CD41 levels in kidney homogenates. We found that intrarenal fibrin(ogen) and CD41 levels (determined by Western blot), VWF and PAI-1 content (determined by ELISA) were significantly increased in Adamts13 −/− diabetic mice compared with WT diabetic mice (P<0.05; Figure 3A through 3C). Consistent with these findings, PAI-1 mRNA expression levels were increased in kidney homogenates of Adamts13 −/− diabetic mice (P<0.05 versus WT diabetic mice; Figure SIV in the online-only Data Supplement). Furthermore, we found an increase in intravascular platelet microthrombi (CD41-positive platelet deposits) in the glomeruli of Adamts13 −/− diabetic mice (P<0.05 versus WT diabetic mice, Figure 3D ). Together, these results suggest that ADAMTS13 deficiency exacerbates intrarenal thrombosis. Next, we evaluated mesangial cell expansion and extracellular matrix (ECM) deposition (fibronectin and collagen) in the kidney glomeruli, 2 key histological features of diabetic nephropathy. Adamts13 −/− diabetic mice exhibited significantly increased glomerular mesangial cell expansion as assessed by periodic acid Schiff staining (P<0.05 versus WT diabetic mice, Figure 4A ). Concomitantly, Adamts13 −/− diabetic mice showed increased ECM deposition and fibrosis as evident by increased fibronectin and collagen accumulation (P<0.05 versus WT diabetic mice, Figure 4B and 4C). Nondiabetic WT or Adamts13 −/− mice showed minimal changes in mesangial cell expansion and ECM deposition ( Figure 4 ). Next, we determined inflammatory cytokines interleukin-1β and tumor necrosis factor-α levels in kidney extracts. Although interleukin-1β and tumor necrosis factor-α levels were significantly increased in both WT and Adamts13 −/− diabetic mice when compared with respective nondiabetic mice, they were comparable between WT diabetic and Adamts13 −/− diabetic mice ( Figure SV in the online-only Data Supplement).
Genetic Deletion of VWF in Adamts13 −/− Mice Improves Kidney Function by Inhibiting Intrarenal Thrombosis and Alleviating Key Hallmark Features of Diabetic Nephropathy
To determine the molecular mechanism by which ADAMTS13 deficiency contributes to diabetic nephropathy exacerbation, we focused on VWF because it is the only known substrate for ADAMTS13 in multiple experimental models. 13, [16] [17] [18] We hypothesized that genetic deletion of VWF in Adamts13 −/− mice will alleviate diabetic nephropathy exacerbation. Blood glucose ( Figure 
Discussion
The key novel findings of this study are (1) diabetes mellitus in mice results in increased VWF levels that are associated with decreased ADAMTS13-specific activity, (2) severe ADAMTS13 deficiency in mice exacerbates diabetic nephropathy, likely mediated, in part, due to increased intrarenal thrombosis, and (3) exacerbation of diabetic nephropathy observed in the setting of ADAMTS13 deficiency is VWF dependent.
We found that WT diabetic mice have significantly low levels of ADAMTS13-specific activity and elevated levels of VWF antigen in the plasma compared with nondiabetic littermates. Our findings are consistent with several population-based studies, which have observed low ADAMTS13 activity and high VWF antigen levels in type 1 and type 2 diabetic patients affected with diabetic nephropathy. 10, 11, 14, 19, 20 The mechanisms by which ADAMTS13-specific activity is reduced in the setting of diabetes mellitus remain unclear. Possible mechanisms include: (1) reduced synthesis and secretion of ADAMTS13 by hepatic stellate cells in the liver; (2) increased ADAMTS13 consumption or incorporation into thrombi together with its substrate VWF, as observed in patients with acute myocardial infarction 21 ; (3) loss of function due to inhibitory autoantibodies to ADAMTS13 22 ; and (4) oxidative modification of ADAMTS13. 23 Clinical studies have suggested that oxidative stress in type 2 diabetic patients affected with diabetic nephropathy is associated with increased ULVWF multimers. 3 However, to date there is no experimental evidence to suggest a causal role for ULVWF multimers in the exacerbation of diabetic nephropathy. One can speculate that ULVWF multimers Vwf −/− mice to determine the role of the ADAMTS13-VWF axis in experimental diabetic nephropathy. Herein, we provide evidence that Adamts13 −/− diabetic mice are more susceptible to diabetic nephropathy and have deteriorated kidney function. Because VWF is the only known substrate for ADAMTS13, 13, 16, 17 we determined whether exacerbated diabetic nephropathy in Adamts13 −/− mice is VWF dependent. We found that genetic deletion of VWF in Adamts13 −/− mice alleviated exacerbated diabetic nephropathy. Together, these results strongly suggest a causal role for the ADAMTS13-VWF axis in the progression of diabetic nephropathy.
It is intriguing to consider possible mechanisms by which the ADAMTS13-VWF axis may contribute to the progression of diabetic nephropathy. Because podocytes and glomerular endothelial cells synthesize ADAMTS13, we hypothesized that ADAMTS13 deficiency may aggravate intrarenal thrombosis in the high shear environment of glomeruli due to the accumulation of platelet-rich microthrombi, and, thereby exacerbate diabetic nephropathy. Spontaneous thrombus formation has been demonstrated in activated microvessels of Adamst13 −/− mice, but not in WT mice. 15 Consistent with this hypothesis, we found that thrombosis markers such as PAI-1, VWF, fibrinogen, and CD41 levels were significantly elevated in kidney homogenates of Adamts13 −/− diabetic mice, suggesting aggravated intrarenal thrombosis. Consistent with these results, we found an increase in intravascular platelet microthrombi (CD41-positive platelet deposits) in the glomeruli of Adamts13 −/− diabetic mice. On basis of these results, we suggest that ADAMTS13, by regulating ULVWF/VWF multimer size, may inhibit thrombotic angiopathy in the setting of diabetes mellitus. Indeed, a recent study has shown that recombinant ADAMTS13 inhibits thrombotic microangiopathy after systemic vascular endothelial growth factor inhibition. 24 We and others have demonstrated that in addition to its role in thrombosis, the ADAMTS13-VWF axis also functions in the modulation of inflammatory responses in experimental models of stroke, myocardial infarction, and atherosclerosis. 16, 18, 25, 26 However, to our surprise, we found that the inflammatory cytokines interleukin-1β and tumor necrosis factor-α were comparable in kidney extracts of Adamts13 −/− diabetic and WT diabetic mice, suggesting that most likely it is the aggravation of intrarenal thrombosis that mediates diabetic nephropathy exacerbation in Adamts13 −/− mice in the setting of diabetes mellitus.
It is known that PAI-1 contributes to diabetic nephropathy exacerbation by regulating TGF-β (transforming growth factor-beta) and renal production of ECM proteins, such as collagen and fibronectin. 27 Accumulation of ECM proteins and mesangial cell expansion in the kidney glomerular and tubular compartments are hallmarks of diabetic nephropathy and worsening of renal function. We found that ADAMTS13 deficiency in mice promotes mesangial cell expansion and accumulation of collagen and fibronectin in the glomerular compartment, which was associated with increased PAI-1 protein levels. Although endothelial cells are the major source of PAI-1, platelets also contain significant amounts of PAI-1. We speculate that the source of increased PAI-1 levels in kidney homogenates of Adamts13 −/− mice is both endothelial cells and activated platelets within thrombi. On the basis of our findings, we proposed a mechanistic model in which ADAMTS13 deficiency combined with hyperglycemia aggravates intrarenal thrombosis. Increased PAI-1 levels are released from activated endothelial cells and platelet-rich thrombi in the tubular microenvironment, which, in turn, potentiate TGF-β production to enhance the production of ECM proteins, including collagen and fibronectin, and thereby exacerbate diabetic nephropathy.
Our studies have some limitations. First, we have used a model of type 1 diabetes mellitus rather than more common type 2 diabetes mellitus. Second, type 2 diabetes mellitus patients with diabetic nephropathy often have only partially reduced ADAMTS13 activity rather than severe ADAMTS13 deficiency. 10, 11, 14 This study did not define whether partially reduced ADAMTS13 levels contribute to diabetic nephropathy exacerbation. Future studies will be required to determine the threshold of ADAMTS13-specific activity required to prevent exacerbated diabetic nephropathy. Despite this limitation, in our opinion, the results from this study may have clinical implications. First, our data suggest that ADAMTS13-VWF imbalance may causally contribute to thrombotic angiopathy in diabetic patients rather than simply serving as a biomarker of endothelial dysfunction and oxidative stress. Second, population-based studies have shown a lower efficacy for aspirin in preventing cardiovascular events in patients diabetes mellitus compared with nondiabetic patients. 28, 29 It is possible that the lower efficacy could be, in part, related to the inability of aspirin to inhibit the formation of ULVWF-rich thrombi in diabetic patients. The use of recombinant ADAMTS13 or N-acetyl cysteine, which is known to reduce hyperactive ULVWF multimers to less active VWF multimers, combined with angiotensin-converting enzyme inhibitors may be helpful in preventing cardiovascular events in diabetic patients.
In summary, for the first time to our knowledge, we show that severe ADAMTS13 deficiency exacerbates diabetic nephropathy, likely mediated by VWF-dependent increased intrarenal thrombosis. Alteration in ADAMTS13-VWF balance may be one of the key pathophysiological mechanisms of increased thrombotic angiopathies observed in diabetic patients.
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